"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Leukemia. 2022 May;36(5):1436-1439. doi: 10.1038/s41375-022-01537-w. Epub 2022 Mar 11.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine
  • Chromosome Deletion
  • Chromosomes, Human, Pair 5 / genetics
  • Humans
  • Karyotype
  • Lenalidomide / therapeutic use
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics

Substances

  • Lenalidomide
  • Azacitidine